These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 33161206)

  • 1. Corrigendum to "In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation" [Biochem. Pharmacol. 123(2017)85-96].
    Sager JE; Tripathy S; Price LSL; Nath A; Chang J; Stephenson-Famy A; Isoherranen N
    Biochem Pharmacol; 2021 Jan; 183():114306. PubMed ID: 33161206
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation.
    Sager JE; Tripathy S; Price LS; Nath A; Chang J; Stephenson-Famy A; Isoherranen N
    Biochem Pharmacol; 2017 Jan; 123():85-96. PubMed ID: 27836670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction.
    Reese MJ; Wurm RM; Muir KT; Generaux GT; St John-Williams L; McConn DJ
    Drug Metab Dispos; 2008 Jul; 36(7):1198-201. PubMed ID: 18420781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model.
    Xue C; Zhang X; Cai W
    Pharmaceutics; 2017 Dec; 10(1):. PubMed ID: 29267251
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change from the CYP2D6 extensive metabolizer to the poor metabolizer phenotype during treatment With bupropion.
    Güzey C; Norström A; Spigset O
    Ther Drug Monit; 2002 Jun; 24(3):436-7. PubMed ID: 12021638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude.
    Venkatakrishnan K; Obach RS
    Drug Metab Dispos; 2005 Jun; 33(6):845-52. PubMed ID: 15788540
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chirality and neuropsychiatric drugs: an update on stereoselective disposition and clinical pharmacokinetics of bupropion.
    Dash RP; Rais R; Srinivas NR
    Xenobiotica; 2018 Sep; 48(9):945-957. PubMed ID: 28876959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition.
    VandenBrink BM; Foti RS; Rock DA; Wienkers LC; Wahlstrom JL
    Drug Metab Dispos; 2012 Jan; 40(1):47-53. PubMed ID: 21976621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of CYP2D6 activity by bupropion.
    Kotlyar M; Brauer LH; Tracy TS; Hatsukami DK; Harris J; Bronars CA; Adson DE
    J Clin Psychopharmacol; 2005 Jun; 25(3):226-9. PubMed ID: 15876900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bupropion plasma levels and CYP2D6 phenotype.
    Pollock BG; Sweet RA; Kirshner M; Reynolds CF
    Ther Drug Monit; 1996 Oct; 18(5):581-5. PubMed ID: 8885123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genotype-sensitive reversible and time-dependent CYP2D6 inhibition in human liver microsomes.
    Storelli F; Desmeules J; Daali Y
    Basic Clin Pharmacol Toxicol; 2019 Feb; 124(2):170-180. PubMed ID: 30192434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Cytochrome P450 2D6 Function on the Chiral Blood Plasma Pharmacokinetics of 3,4-Methylenedioxymethamphetamine (MDMA) and Its Phase I and II Metabolites in Humans.
    Steuer AE; Schmidhauser C; Tingelhoff EH; Schmid Y; Rickli A; Kraemer T; Liechti ME
    PLoS One; 2016; 11(3):e0150955. PubMed ID: 26967321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rolapitant Is a Reversible Inhibitor of CYP2D6.
    Glass SM; Leddy SM; Orwin MC; Miller GP; Furge KA; Furge LL
    Drug Metab Dispos; 2019 Jun; 47(6):567-573. PubMed ID: 30952677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS.
    Borkar RM; Bhandi MM; Dubey AP; Ganga Reddy V; Komirishetty P; Nandekar PP; Sangamwar AT; Kamal A; Banerjee SK; Srinivas R
    Biomed Chromatogr; 2016 Oct; 30(10):1556-72. PubMed ID: 27006091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of CYP2B6*6 on Steady-State Serum Concentrations of Bupropion and Hydroxybupropion in Psychiatric Patients: A Study Based on Therapeutic Drug Monitoring Data.
    Høiseth G; Haslemo T; Uthus LH; Molden E
    Ther Drug Monit; 2015 Oct; 37(5):589-93. PubMed ID: 25565674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chiral Plasma Pharmacokinetics and Urinary Excretion of Bupropion and Metabolites in Healthy Volunteers.
    Masters AR; Gufford BT; Lu JB; Metzger IF; Jones DR; Desta Z
    J Pharmacol Exp Ther; 2016 Aug; 358(2):230-8. PubMed ID: 27255113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study.
    Spanakis M; Vizirianakis IS; Mironidou-Tzouveleki M; Niopas I
    Biomed Chromatogr; 2009 Nov; 23(11):1131-7. PubMed ID: 19444798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corrigendum to 'Anti-thrombotic efficacy of S007-867: Pre-clinical evaluation in experimental models of thrombosis in vivo and in vitro' [Biochem. Pharmacol. 148 (2018) 288-297].
    Misra A; Prakash P; Aggarwal H; Dhankani P; Kumar S; Prakash Pandey C; Pugh N; Bihan D; Kumar Barthwal M; Farndale RW; Kumar Dikshit D; Dikshit M
    Biochem Pharmacol; 2018 Dec; 158():229-231. PubMed ID: 30390497
    [No Abstract]   [Full Text] [Related]  

  • 19. Inhibitory Mechanisms of Human CYPs by Three Alkaloids Isolated from Traditional Chinese Herbs.
    Zhao Y; Hellum BH; Liang A; Nilsen OG
    Phytother Res; 2015 Jun; 29(6):825-34. PubMed ID: 25640685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atomoxetine hydrochloride: clinical drug-drug interaction prediction and outcome.
    Sauer JM; Long AJ; Ring B; Gillespie JS; Sanburn NP; DeSante KA; Petullo D; VandenBranden MR; Jensen CB; Wrighton SA; Smith BP; Read HA; Witcher JW
    J Pharmacol Exp Ther; 2004 Feb; 308(2):410-8. PubMed ID: 14610241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.